Home 2018-01-31T15:53:20+00:00


Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a not-for-profit organisation, founded in 2000 with the mission to perform research and provide scientific, economic and regulatory consultancy for innovation in the health sector at European level. The main fields of interest are life sciences and biotechnologies, drug development for small populations (pediatric and rare diseases), research management andmethodology, monitoring, statistics, regulatory, ethics and pharmacovigilance.

Who we are


Development and application of innovative methodologies in clinical trials for small populations, management of disease registries, execution of studies in the pharmacological field. Find out more.
Development and supervision of dossiers and documentation regarding national and European authorisation procedures for medicinal products. Find out more.
Development and management of all clinical trial phases, which are performed by the Consortium both as a Sponsor and as a Contract Research Organisation (CRO). Find out more.
Educational activities addressed to public bodies, research institutes and private companies, also within CME programmes. Find out more.
Management and participation to medical research projects and consortiums at national and international level. Find out more.
Design and management of registries and drug databases. Find out more.
Research networks aimed to facilitate transfer of know-how and to promote national and international research as well as scientific excellence. Find out more.
CVBF Brochure

On-going Projects

Slide background
Slide background
Slide background
Slide backgroundSlide thumbnail
Closed logo
logo innermed

Latest News

903, 2018

DEEP Final meeting: preliminary results

The DEEP (DEferiprone Evaluations in paediatrics) project, a 6-year European Project (FP7) coordinated by CVBF and comprising 23 recruiting centres in European and non-European countries, scientific partners from several European countries and a pharmaceutical group based [...]

503, 2018

Orphan medicinal products in Europe: an analysis of marketing authorisation failures and abandoned drugs

On September 2017, the article “Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs” was published on BMJ Openjournal. The paper reports the results [...]